May 27, 2026
California's Department of Cannabis Control issued a Notice of Emergency Rulemaking this month that would let operators currently holding combined Medicinal-and-Adult-Use designations be re-issued as separate Medicinal (M) and Adult-Use (A) licenses on an expedited basis. The change is the state's first concrete response to the Justice Department's April 23, 2026 order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act. It takes effect immediately upon approval by the Office of Administrative Law, with public comment open through the OAL review window.
The emergency action, referenced by the DCC as "Modifications to A- and M-designation," does not change who can hold a California cannabis license. It changes the form of the license. Under existing DCC regulations, retailers and microbusinesses can operate under a combined A/M designation that authorizes both adult-use and medicinal activity at the same premises. The emergency rulemaking would let those operators apply to have that single combined license split into two — one M-only license and one A-only license — through an expedited process. DCC's notice indicates the rulemaking would also accommodate, in some cases, issuance of the new licenses to a different legal entity than the one currently holding the combined license, provided certain compliance requirements are met.
DCC estimates the change is potentially relevant to roughly 1,600 licensed retailers and microbusinesses statewide. The Department's stated rationale is that California medical marijuana licensees have only 60 days from Federal Register publication of the April 23 DOJ order to submit a DEA registration application and continue operating under their state license while DEA processes it. That window expires on or about June 22, 2026. Without a separate M-only license, applicants face structural and identity-of-applicant questions that complicate their federal filings.
Public comments must reference the topic "Modifications to A- and M-designation" and state that they concern an emergency rulemaking action under OAL review.
For California operators currently holding an A/M designation, several concrete actions are worth considering with counsel:
The first is a structural decision. Splitting a single combined license into two separate licenses changes the entity-to-license relationship at the premises and can affect ownership disclosures, financier reporting, and local conditional-use permits. Operators that have layered investor or management-services structures over a single A/M license should plan for downstream paperwork in addition to the DCC filing itself.
The second is a timing decision. The 60-day federal window for state medical licensees to file a DEA registration application — and continue operations under state license while DEA processes that application — is short. The DCC's expedited process is designed to land in time, but operators who wait for the emergency regulation to be approved by OAL before beginning their internal preparation will be compressing every downstream step against the same June 22, 2026 deadline.
The third is a compliance decision. The emergency rulemaking is framed as a pathway for operators who want to pursue DEA registration. Operators who do not intend to pursue federal registration are not required to split their licenses. Whether splitting is worth it depends on the operator's medical-customer mix, expected federal regulatory exposure, and whether the operator views Schedule III placement as a tax, banking, or research opportunity worth the additional federal compliance burden. Talk to your counsel about your situation.
The fourth is a public-comment decision. The notice is open for comment, and the DCC is on a tight enough timeline that substantive operator input — particularly around how local-government conditional approvals interact with the expedited path — has a reasonable chance of being heard.
California is the first major adult-use state to issue a rulemaking explicitly tied to the April 23 DOJ rescheduling order. Other large-market states have not yet posted comparable notices. New York's Office of Cannabis Management has not issued an analogous separation rule for the state's combined licenses; Massachusetts' Cannabis Control Commission is in the middle of a broader modernization bill but has not surfaced a comparable expedited-license pathway. Colorado's Marijuana Enforcement Division has not posted an emergency rule. Operators with multi-state footprints should expect uneven state response timing in the coming weeks.
The DOJ order itself is narrower than a full reclassification: it placed only FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, leaving adult-use cannabis in Schedule I pending the broader administrative hearing currently set to begin June 29, 2026. NORML, Smart Approaches to Marijuana, and MMJ International Holdings, among others, have filed Notices of Intent to Participate in that hearing.
Three near-term dates matter for operators tracking this rulemaking:
Whether the California pathway functions as designed will depend on OAL approval timing and on how DEA processes the first wave of California applications. Litigation challenging the April 23 DOJ order is already pending; the rescheduling timetable remains subject to administrative and judicial review.
This article is informational and does not constitute legal advice. California cannabis operators considering splitting an A/M license or applying for DEA registration should consult with cannabis regulatory counsel about the specifics of their license, ownership structure, and federal exposure.
California's Department of Cannabis Control issued a Notice of Emergency Rulemaking this month that would let operators currently holding combined Medicinal-and-Adult-Use designations be re-issued as separate Medicinal (M) and Adult-Use (A) licenses on an expedited basis. The change is the state's first concrete response to the Justice Department's April 23, 2026 order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act. It takes effect immediately upon approval by the Office of Administrative Law, with public comment open through the OAL review window.
The emergency action, referenced by the DCC as "Modifications to A- and M-designation," does not change who can hold a California cannabis license. It changes the form of the license. Under existing DCC regulations, retailers and microbusinesses can operate under a combined A/M designation that authorizes both adult-use and medicinal activity at the same premises. The emergency rulemaking would let those operators apply to have that single combined license split into two — one M-only license and one A-only license — through an expedited process. DCC's notice indicates the rulemaking would also accommodate, in some cases, issuance of the new licenses to a different legal entity than the one currently holding the combined license, provided certain compliance requirements are met.
DCC estimates the change is potentially relevant to roughly 1,600 licensed retailers and microbusinesses statewide. The Department's stated rationale is that California medical marijuana licensees have only 60 days from Federal Register publication of the April 23 DOJ order to submit a DEA registration application and continue operating under their state license while DEA processes it. That window expires on or about June 22, 2026. Without a separate M-only license, applicants face structural and identity-of-applicant questions that complicate their federal filings.
Public comments must reference the topic "Modifications to A- and M-designation" and state that they concern an emergency rulemaking action under OAL review.
For California operators currently holding an A/M designation, several concrete actions are worth considering with counsel:
The first is a structural decision. Splitting a single combined license into two separate licenses changes the entity-to-license relationship at the premises and can affect ownership disclosures, financier reporting, and local conditional-use permits. Operators that have layered investor or management-services structures over a single A/M license should plan for downstream paperwork in addition to the DCC filing itself.
The second is a timing decision. The 60-day federal window for state medical licensees to file a DEA registration application — and continue operations under state license while DEA processes that application — is short. The DCC's expedited process is designed to land in time, but operators who wait for the emergency regulation to be approved by OAL before beginning their internal preparation will be compressing every downstream step against the same June 22, 2026 deadline.
The third is a compliance decision. The emergency rulemaking is framed as a pathway for operators who want to pursue DEA registration. Operators who do not intend to pursue federal registration are not required to split their licenses. Whether splitting is worth it depends on the operator's medical-customer mix, expected federal regulatory exposure, and whether the operator views Schedule III placement as a tax, banking, or research opportunity worth the additional federal compliance burden. Talk to your counsel about your situation.
The fourth is a public-comment decision. The notice is open for comment, and the DCC is on a tight enough timeline that substantive operator input — particularly around how local-government conditional approvals interact with the expedited path — has a reasonable chance of being heard.
California is the first major adult-use state to issue a rulemaking explicitly tied to the April 23 DOJ rescheduling order. Other large-market states have not yet posted comparable notices. New York's Office of Cannabis Management has not issued an analogous separation rule for the state's combined licenses; Massachusetts' Cannabis Control Commission is in the middle of a broader modernization bill but has not surfaced a comparable expedited-license pathway. Colorado's Marijuana Enforcement Division has not posted an emergency rule. Operators with multi-state footprints should expect uneven state response timing in the coming weeks.
The DOJ order itself is narrower than a full reclassification: it placed only FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, leaving adult-use cannabis in Schedule I pending the broader administrative hearing currently set to begin June 29, 2026. NORML, Smart Approaches to Marijuana, and MMJ International Holdings, among others, have filed Notices of Intent to Participate in that hearing.
Three near-term dates matter for operators tracking this rulemaking:
Whether the California pathway functions as designed will depend on OAL approval timing and on how DEA processes the first wave of California applications. Litigation challenging the April 23 DOJ order is already pending; the rescheduling timetable remains subject to administrative and judicial review.
This article is informational and does not constitute legal advice. California cannabis operators considering splitting an A/M license or applying for DEA registration should consult with cannabis regulatory counsel about the specifics of their license, ownership structure, and federal exposure.
